论文信息 - Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis - 字舞流文

Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis

M. D. de Bruin‐Weller | T. Nakahara | A. Shabbir | M. Deleuran | R. Bissonnette | L. Beck | S. Seo | J. O’Malley | R. Galus | N. Levit | F. Khokhar | Jignesh Vakil | Jing Xiao | Ainara Rodríguez Marco | A. R. Marco